press

Medwatch 25. september 2024

Medtech company Otivio is on a strong trajectory as it moves toward commercializing its pressure boot, Flowox, designed for multiple sclerosis (MS) patients. The company recently received CE marking for Flowox, indicating its approval for use with MS patients. Furthermore, promising results have been noted regarding the treatment of spasticity in MS patients.

Medwatch 25. september 2024 Read More »

Otivio raised NOK 40 million.

In the second quarter of this year, Otivio raised NOK 40 million for the continued development of a ground-breaking new low risk method for symptoms management of multiple sclerosis. New investors signed for NOK 22 million, existing investors for NOK 14 million and board of directors and management the remaining NOK 4 million.

“We are very pleased to have landed the issue under the prevailing market conditions”, says Andreas Mollatt, CEO Otivio, and continues: “Realizing the values ​​that lie in the treatment of MS symptoms is of course exciting”. “But perhaps the most motivating thing is to be able to offer people with MS a novel and low-risk method to treat these symptoms that has such a negative impact on their quality of life”.

Otivio raised NOK 40 million. Read More »

Scroll to Top